eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer
eFFECTOR Therapeutics Inc (NASDAQ:EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal…
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Baylor College Of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development Of Zotatifin In Triple-Negative Breast Cancer At 2021 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
eFFECTOR Therapeutics (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine, today
Mizuho Initiates Coverage On eFFECTOR Therapeutics with Buy Rating, Announces Price Target of $20
Mizuho analyst Mara Goldstein initiates coverage on eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy rating and announces Price Target of $20.
48 Biggest Movers From Yesterday
Gainers
Gogo Inc. (NASDAQ: GOGO) shares climbed 37.6% to close at $16.82 on Tuesday after the company raised the long-term financial targets announced during Q4 2020 earnings.
